Back to Search
JASON FISCHEL, M.D.
M.D.
Emergency Medicine Physician
NPI: 1689879082IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
MD440501(PA)MT191679(PA)493333(CT)
CMS Specialties
PrimaryEMERGENCY MEDICINE
Education
OTHER
Class of 2007
Research & Publications (20)
Impact of erythropoietin on the effects of irradiation under hypoxia.
PMID 19499245·J Cancer Res Clin Oncol·2009
8-other
Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.
PMID 19542251·Ann Oncol·2009
7-preclinical
Emerging molecular targeted therapies in the treatment of head and neck cancer.
PMID 19519286·Expert Opin Emerg Drugs·2009
6-review
Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.
PMID 18577994·Br J Cancer·2008
7-preclinical
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.
PMID 18494832·BJU Int·2008
8-other
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition.
PMID 18691881·Eur J Cancer·2008
7-preclinical
Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression.
PMID 18607838·Acta Oncol·2008
7-preclinical
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
PMID 17593391·J Cancer Res Clin Oncol·2008
7-preclinical
EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
PMID 17324578·Crit Rev Oncol Hematol·2007
6-review
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.
PMID 17693647·Ann Oncol·2007
3-trial
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience.
PMID 16721126·Curr Opin Oncol·2006
6-review
Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.
PMID 16940984·Br J Cancer·2006
4-observational
Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
PMID 16926630·Anticancer Drugs·2006
8-other
Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.
PMID 15756277·Br J Cancer·2005
8-other
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation.
PMID 16373711·Mol Cancer Ther·2005
8-other
The impact of preschool inattention, hyperactivity, and impulsivity on social and academic development: a review.
PMID 15972069·J Child Psychol Psychiatry·2005
6-review
Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
PMID 15919200·Eur J Cancer·2005
7-preclinical
Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells.
PMID 15711183·Anticancer Drugs·2005
8-other
Predicting improvement after first-grade reading difficulties: the effects of oral language, emergent literacy, and behavior skills.
PMID 15656751·Dev Psychol·2005
8-other
Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
PMID 15571968·Eur J Cancer·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 30 SHELBURNE RD
STAMFORD, CT 06902 - Phone
- (203) 276-7777
Quick Facts
- NPI
- 1689879082
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 19
- Publications
- 20
Are you this provider?
Claim Your Profile